Corticosteroids for Dengue - Why Don't They Work?

Thi Hanh Tien Nguyen, Quyen Than Ha Nguyen, Tuan Trung Vu, Jeremy Farrar, Long Truong Hoang, Thi Hoai Tam Dong, Van Ngoc Tran, Lam Khanh Phung, Marcel Wolbers, Stephen S. Whitehead, Martin L. Hibberd, Bridget Wills, Cameron P. Simmons

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)


Background:Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue.Findings:In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels.Conclusion:The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.

Original languageEnglish
Article numbere2592
JournalPLoS Neglected Tropical Diseases
Issue number12
Publication statusPublished - 2013
Externally publishedYes

Cite this